Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has strengthened its leadership, appointing experienced biotechnology executive Dr Bradley Glover as Non-Executive Director and Chair, and naming a new Chief Financial Officer, as part of a broader governance refresh. …
Chimeric Therapeutics names experienced biotech leader as chair in board and executive refresh
February 16, 2026 Australian BiotechBioPharmaDispatch Executive
Latest Video
New Stories
-
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News